In a paper published last week in ACR Open Rheumatology, researchers reported that although patients had some concerns about safety and efficacy, overall, they were satisfied with the switch to a biosimilar.
While reports of patient attitudes toward switching from reference infliximab to biosimilars are growing in number in the European context, fewer reports are available about US patients’ experiences with and attitudes toward nonmedical switching. In a paper published last week in ACR Open Rheumatology, researchers reported that although patients had some concerns about safety and efficacy, overall, they were satisfied with the switch to a biosimilar.
The researchers conducted a cross-sectional survey of adults treated for rheumatologic diseases in the Kaiser Permanente Colorado health system, which implemented a switch to biosimilar infliximab, Inflectra, from the reference Remicade in 2017 for patients with rheumatoid arthritis (RA), psoriatic arthritis, and ankylosing spondylitis.
In total, 108 patients qualitied for the switch, and 52 consented to be surveyed by telephone. Overall, the patients surveyed tended to be older, female, white, diagnosed with RA, enrolled in a Medicare plan, and experiencing moderate disease burden. At the time of the survey, 76.9% of patients reported that their current therapy was the biosimilar, whereas 23.1% reported that they were receiving the reference infliximab.
Overall, in both those who had and had not switched, patients had been receiving biologic therapy for a mean of 9.3 years, and 84.6% of patients said that they were satisfied with their current treatment in terms of disease control; 80% of patients who switched reported being satisfied, and 100% of patients who did not switch reported the same.
Although approximately one-third (32.7%) of patients said that they had heard of the biosimilar previously, 35.8% said they did not know enough about the safety and efficacy of the biosimilar before the switch. Some were worried that the biosimilar would be too expensive (13.5%), could have side effects (38.5%), or might result in loss of disease control after the switch (38.5%). Among patients who did not switch, 58.3% said that they were not confident that there was enough information available to undertake the switch.
According to the paper’s authors, this survey identified that, in general, patients who switched and those who did not were satisfied with their current therapy, though they had some concerns about switching. “Patient involvement in the switching decision‐making process may allay concerns and enhance [biosimilar] uptake,” write the authors.
Finally, the authors acknowledge that the relatively small sample size and the fact that the survey was conducted in one healthcare system limit the generalizability of these findings.
Reference
Chau J, Delate T, Ota T, Bhardwaja B. Patient perspectives on switching from infliximab to infliximab-dyyb in patients with rheumatologic diseases in the United States [published online March 15, 2019]. ACR Open Rheumatology.
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Early Success of Adalimumab Biosimilars Featured at AMCP 2025
April 5th 2025High adherence rates, comparable clinical effectiveness, and cost savings have marked the early adoption of adalimumab biosimilars in the US, particularly in formulary-driven transitions, as shown in 2 retrospective studies presented at the Academy of Managed Care Pharmacy annual meeting (AMCP 2025).